Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy
Arielle Elkrief(Centre Hospitalier de l’Université de Montréal), Adam J. Schoenfeld(Memorial Sloan Kettering Cancer Center), Antoine Desîlets(Centre Hospitalier de l’Université de Montréal), Daniel J. Kelly(Trinity College Dublin), Marc Ladanyi(Memorial Sloan Kettering Cancer Center), Charles M. Rudin(Memorial Sloan Kettering Cancer Center), Meriem Messaoudene(Centre Hospitalier de l’Université de Montréal), Pooja Gogia(Memorial Sloan Kettering Cancer Center), Eder Orlando Méndez-Salazar(Université de Montréal), Lisa Derosa(Institut Gustave Roussy), Bertrand Routy(Centre Hospitalier de l’Université de Montréal), Laurence Zitvogel(Institut Gustave Roussy), Chad Vanderbilt(Memorial Sloan Kettering Cancer Center), Jade Maillou(Université de Montréal), Matthew D. Hellmann(AstraZeneca (United States))
Cited by 54
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|2.3k